Report of Foreign Issuer (6-k)
December 05 2016 - 9:31AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
December 5, 2016
uniQure N.V.
Matthew Kapusta, Interim Chief Executive Office and Chief Financial Officer
Meibergdreef 61
Amsterdam 1105 BA, the Netherlands; Tel: +31-20-240-6000
(Address, Including ZIP Code, and Telephone Number,
Including Area Code, of Registrants Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F
x
Form 40-F
o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
o
Furnished as Exhibit 99.1 to this Report on Form 6-K is a press release of uniQure N.V. (the
Company
), dated December 4, 2016, announcing the first clinical data from the second dose cohort of AMT-060 in the ongoing Phase I/II trial in patients with severe Hemophilia B.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
UNIQURE N.V.
|
|
|
|
Date: December 5, 2016
|
By:
|
/S/ MATTHEW KAPUSTA
|
|
|
Matthew Kapusta
|
|
|
Interim Chief Executive Officer and Chief
Financial Officer
|
3
INDEX TO EXHIBITS
Number
|
|
Description
|
|
|
|
99.1
|
|
Press release of uniQure N.V., dated December 4, 2016, announcing the first clinical data from the second dose cohort of AMT-060 in the ongoing Phase I/II trial in patients with severe Hemophilia B.
|
4
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Aug 2024 to Sep 2024
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Sep 2023 to Sep 2024